Pregnenolone
- Generic Name
- Pregnenolone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32O2
- CAS Number
- 145-13-1
- Unique Ingredient Identifier
- 73R90F7MQ8
- Background
A 21-carbon steroid, derived from cholesterol and found in steroid hormone-producing tissues. Pregnenolone is the precursor to gonadal steroid hormones and the adrenal corticosteroids.
- Associated Conditions
- -
- Associated Therapies
- -
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 170
- Registration Number
- NCT01956279
- Locations
- ๐บ๐ธ
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 94
- Registration Number
- NCT01898013
- Locations
- ๐บ๐ธ
Durham VA Medical Center, Durham, North Carolina, United States
A Study of Pregnenolone in the Treatment of Individuals With Autism
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 15
- Registration Number
- NCT01881737
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Study Using Pregnenolone to Treat Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT01409096
- Locations
- ๐บ๐ธ
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 53
- Registration Number
- NCT01336413
- Locations
- ๐บ๐ธ
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00993629
- Locations
- ๐บ๐ธ
VA Medical Center, Durham, Durham, North Carolina, United States
Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- National Research Foundation, Singapore
- Target Recruit Count
- 120
- Registration Number
- NCT00894842
- Locations
- ๐ธ๐ฌ
Institute of Mental Health, Singapore, Singapore
Adjunctive Pregnenolone in Veterans With Mild TBI
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00623506
- Locations
- ๐บ๐ธ
Durham VA Medical Center, Durham, North Carolina, United States
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Durham VA Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT00560937
- Locations
- ๐บ๐ธ
Durham VAMC, Durham, North Carolina, United States
Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT00223197
- Locations
- ๐บ๐ธ
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.